Center for Genetic Engineering and Biotechnology (CIGB): CIGB-66

Center for Genetic Engineering and Biotechnology (CIGB): CIGB-66

Vaccine Type: Protein Subunit

This vaccine may also be referred to as Abdala

About Trial Phases

Phase 1: 2 Trials

RPCEC00000345
Cuba
RPCEC00000346
Cuba

Phase 2: 2 Trials

RPCEC00000345
Cuba
RPCEC00000346
Cuba

Phase 3: 1 Trial

RPCEC00000359
Cuba

Approvals

This vaccine is not yet approved.

Registered Trials

RPCEC00000359
Phase 3
Cuba
Total Enrollment: 48,000
Official Trial Registration:
- RPCEC00000359(Opens in new tab/window)
RPCEC00000345
Phase 1/2
Cuba
Total Enrollment: 88
Official Trial Registration:
- RPCEC00000345(Opens in new tab/window)
RPCEC00000346
Phase 1/2
Cuba
Total Enrollment: 132
Official Trial Registration:
- RPCEC00000346(Opens in new tab/window)

© 2021 McGill COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

The information provided on this site is for informational purposes only and should not be considered to be medical advice or an indication of an endorsement. All information is based on publicly available data.

Site Credits Website Feedback Form